Drug interactions in HIV-infected patients treated for hepatitis C

References

• WHO/UNAIDS working group on global HIV/AIDS and STI surveillance. [ cited 2017 Jan 5]. Available from: http://www.who.int/hiv/data/epi
   Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:45–57.
   PubMed Web of Science ®Google Scholar
• Ly K, Xing J, Klevens R, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–278.
   PubMed Web of Science ®Google Scholar
• Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797–808.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Fernandez-Montero JV, De Mendoza C, et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res. 2014;105:1–7.
   PubMed Web of Science ®Google Scholar
• Soriano V, Labarga P, De Mendoza C, et al. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int. 2016;36:763.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Rockstroh J, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany - a case-control study. PLoS One. 2011;6:e17781.
   PubMed Web of Science ®Google Scholar
• Sánchez C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. 2013;33:1357–1362.
   PubMed Web of Science ®Google Scholar
• Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother. 2008;62:1–4.
   PubMed Web of Science ®Google Scholar
• Fernandez-Montero JV, Eugenia E, Barreiro P, et al. Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. Expert Opin Drug Saf. 2013;12:697–707.
   PubMed Web of Science ®Google Scholar
• DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [ cited 2017 Apr 21]. Available from: http://aidsinfo.nih.gov/e-news
   Google Scholar
• European AIDS Clinical Society Guidelines. Clinical management and treatment of HIV infected adults in Europe. 2016 Oct [cited 2017 Apr 21]. Available from: http://www.eacsociety.org/Portals/0/GUIDELINES/
   Google Scholar
• Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14:168–178.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12:374–382.
   PubMed Web of Science ®Google Scholar
• Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat. 2011;18:11–16.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski M, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with HCV genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
   PubMed Web of Science ®Google Scholar
• Kowdley K, Gordon S, Reddy K, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
   PubMed Web of Science ®Google Scholar
• IDSA/AASLD. Recommendations for testing, managing, and treating hepatitis C. [ cited 2017 Jan 5]. Available from: http://www.hcvguidelines.org
   Google Scholar
• EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
   PubMedGoogle Scholar
• Foster G, Afdhal N, Roberts S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Terrault N. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.
   PubMed Web of Science ®Google Scholar
• Toussaint-Miller K, Andres J. A special touch: treatment considerations for unique patient populations with HCV genotype 1 infection. Ann Pharmacother. 2015;49:1015–1030.
   PubMed Web of Science ®Google Scholar
• Molina JM, Orkin C, Iser D, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098–1106.
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Eron J, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 2015;313:1223–1231.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 2015;313:1232–1239.
   PubMed Web of Science ®Google Scholar
• Kaur K, Gandhi M, Slish J. Drug-drug interactions among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) medications. Infect Dis Ther. 2015;4:159–172.
   PubMed Web of Science ®Google Scholar
• Lo Re V, Kallan M, Tate J, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160:369–379.
   PubMed Web of Science ®Google Scholar
• Labarga P, Fernandez-Montero JV, Lopez M, et al. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies. Antivir Ther. 2014;19:799–803.
   PubMed Web of Science ®Google Scholar
• Fernandez-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–1553.
   PubMed Web of Science ®Google Scholar
• Lee M, Yang H, Lu S, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477.
   PubMed Web of Science ®Google Scholar
• Soriano V, Labarga P, Fernandez-Montero JV, et al. Hepatitis C cure with antiviral therapy - benefits beyond the liver. Antivir Ther. 2016;21:1–8.
   PubMed Web of Science ®Google Scholar
• COHERE. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433–445.
   PubMed Web of Science ®Google Scholar
• Gallego L, Barreiro P, Del Río R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis. 2004;38:430–432.
   PubMed Web of Science ®Google Scholar
• Muñoz-Moreno J, Fumaz C, Ferrer M, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioral review. AIDS Rev. 2009;11:103–109.
   PubMed Web of Science ®Google Scholar
• Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010;12:67–75.
   PubMed Web of Science ®Google Scholar
• Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457–477.
   PubMed Web of Science ®Google Scholar
• Leslie E, Deeley R, Cole S. Multidrug resistance proteins: role of p-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–237.
   PubMed Web of Science ®Google Scholar
• Wessler J, Grip L, Mendell J, et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–2502.
   PubMed Web of Science ®Google Scholar
• Chtioui H, Buclin T, Moradpour D. New hepatitis C treatments: pharmacological considerations and potential for drug interactions. Rev Med Suisse. 2014;10:1600–1604.
   PubMedGoogle Scholar
• MacBrayne C, Kiser J. Pharmacologic considerations in the treatment of hepatitis C virus in persons with HIV. Clin Infect Dis. 2016;63(suppl 1):12–23.
   Web of Science ®Google Scholar
• Bunnell K, Vibhakar S, Glowacki R, et al. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy. 2016;36:e148–53.
   PubMed Web of Science ®Google Scholar
• Khatri A, Dutta S, Dunbar M, et al. Evaluation of drug-drug interactions between direct-acting Anti-Hepatitis C Virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine. Antimicrob Agents Chemother. 2016;60:2965–2971.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409–416.
   PubMed Web of Science ®Google Scholar
• Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis. 2013;45(suppl):343–348.
   Google Scholar
• Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Exp Opin Drug Metab Toxicol. 2015;11:333–341.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos D, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27:36–45.
   PubMed Web of Science ®Google Scholar
• Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792–800.
   PubMed Web of Science ®Google Scholar
• Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
   PubMed Web of Science ®Google Scholar
• Burgess S, Partovi N, Yoshida E, et al. A review of drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015;49:674–687.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Crawford-Jones A, Orkin C. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert Rev Clin Pharmacol. 2014;7:691–704.
   PubMed Web of Science ®Google Scholar
• Bonora S, Puoti M. Use of daclatasvir in HCV/HIV-Coinfected patients in a real-life setting. AIDS Rev. 2017;19:24–34.
   PubMed Web of Science ®Google Scholar
• Merli M, Galli L, Marinaro L, et al. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. J Antimicrob Chemother. 2017;72:812–815.
   PubMed Web of Science ®Google Scholar
• Reese M, Savina P, Generaux G, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353–361.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, De Mendoza C, et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther. 2016;21:91–92.
   PubMed Web of Science ®Google Scholar
• Kwo P, Badshah M. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20:235–241.
   PubMed Web of Science ®Google Scholar
• Minaei A, Kowdley K. ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2015;16:929–937.
   PubMed Web of Science ®Google Scholar
• Dore G, Altice F, Litwin A, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165:625–634.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis G. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 2014;27:331–337.
   PubMedGoogle Scholar
• Koff R. The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39:478–487.
   PubMed Web of Science ®Google Scholar
• Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12:284–292.
   PubMed Web of Science ®Google Scholar
• Fazel Y, Lam B, Golabi P, et al. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf. 2015;14:1317–1326.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23:689–696.
   PubMed Web of Science ®Google Scholar
• Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016;95:e5146.
   PubMed Web of Science ®Google Scholar
• Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404–1412.
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy K. The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015;42:258–272.
   PubMed Web of Science ®Google Scholar
• Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18:931–940.
   PubMed Web of Science ®Google Scholar
• Coppola N, Martini S, Pisaturo M, et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol. 2015;4:1–12.
   PubMedGoogle Scholar
• Alqahtani S, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62:25–30.
   PubMed Web of Science ®Google Scholar
• Mogalian E, German P, Kearney B, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55:605–613.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane E, Peng C, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164–175.
   PubMed Web of Science ®Google Scholar
• Gane E, Poordad F, Wang S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151:651–659.
   PubMed Web of Science ®Google Scholar
• Tong L, Yu W, Chen L, et al. The discovery of ruzasvir (MK-8408): a potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms. J Med Chem. 2017;60:290–306.
   PubMed Web of Science ®Google Scholar
• Kwo P, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. Forthcoming.
   Web of Science ®Google Scholar
• Jacobson I, Lawitz E, Gane E, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.
   PubMed Web of Science ®Google Scholar
• Macías J, Monge P, Mancebo M, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med. Forthcoming.
   Web of Science ®Google Scholar
• Martinello M, Dore G, Skurowski J, et al. Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2016;3:ofw105.
   PubMed Web of Science ®Google Scholar
• Crauwels H, van Heeswijk R, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87–101.
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Bombana E, Rizzi M. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Rev Anti Infect Ther. 2014;12:13–29.
   PubMed Web of Science ®Google Scholar
• Binda C, Tortora A, Garcovich M, et al. Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):102–111.
   PubMedGoogle Scholar
• Singh H, Del Carmen T, Freeman R, et al. From one syndrome to many: incorporating geriatric consultation into HIV care. Clin Infect Dis. Forthcoming.
   Web of Science ®Google Scholar
• Sasadeusz J. HIV and HCV therapies in 2016: optimal regimens. AIDS Rev. 2016;18:212–221.
   PubMed Web of Science ®Google Scholar